ABSSIAssociation of Business Support Services International
References in periodicals archive ?
Dalbavancin and Oritavancin are IV-only lipoglycopeptides indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates for the treatment of ABSSI caused by Gram-positive microorganisms such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus group.
These three new drugs provide an alternative to the current regime for the treatment for ABSSI.
Study to compare CEM-102 (Fusidic acid) to Linezolid in the treatment of ABSSIs, including those caused by MRSA